Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
5.59
+0.07 (1.27%)
At close: Apr 28, 2026, 4:00 PM EDT
5.59
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT

Aardvark Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
13.795.312.172.7
Research & Development
48.9417.364.487.17
Operating Expenses
62.7322.797.4210.36
Operating Income
-62.73-22.79-7.42-10.36
Interest & Investment Income
5.142.411.420.12
EBT Excluding Unusual Items
-57.59-20.37-5.99-10.24
Gain (Loss) on Sale of Investments
-0.01-0.22-1.22-2.32
Asset Writedown
----1
Pretax Income
-57.59-20.59-7.21-13.56
Net Income
-57.59-20.59-7.21-13.56
Net Income to Common
-57.59-20.59-7.21-13.56
Shares Outstanding (Basic)
20444
Shares Outstanding (Diluted)
20444
Shares Change (YoY)
391.06%0.90%1.78%-
EPS (Basic)
-2.93-5.15-1.82-3.49
EPS (Diluted)
-2.93-5.15-1.82-3.49
Free Cash Flow
-54.27-18.2-5.82-10.54
Free Cash Flow Per Share
-2.77-4.55-1.47-2.71
EBITDA
-62.69-22.77--
D&A For EBITDA
0.040.02--
EBIT
-62.73-22.79-7.42-10.36
Source: S&P Capital IQ. Standard template. Financial Sources.